The IL1B Knockout 769-P Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of the 769-P human clear cell renal cell carcinoma line, targeting IL1B. This heterogeneous pool provides a robust loss-of-function model for interleukin-1 beta (IL-1??) studies, free from clonal selection artifacts.
The 769-P parental cell line is a tumorigenic epithelial model derived from a primary human clear cell adenocarcinoma, widely employed in renal cancer research to investigate signaling, drug responses, and tumor microenvironment interactions. Its epithelial morphology and retention of ccRCC molecular features make it a relevant host for studying inflammation-driven renal carcinoma pathology.
IL1B encodes pro-IL-1??, which is cleaved into the active cytokine by caspase-1 following assembly of the NLRP3 inflammasome with ASC. Secreted IL-1?? binds to the IL-1 receptor complex (IL-1R1/IL-1RAcP), recruiting MyD88 and the kinases IRAK4 and IRAK1. These events activate TRAF6 and TAK1, leading to IKK complex activation, phosphorylation and degradation of I??B??, and nuclear translocation of NF-??B p65. Simultaneously, TAK1 stimulates the MAP kinase cascade, resulting in phosphorylation of JNK, p38, and ERK. Consequently, IL-1?? induces expression of pro-inflammatory genes such as IL-6, IL-8, CXCL1, CCL2, COX-2, and matrix metalloproteinases, while also promoting its own transcription in an autocrine loop. Negative regulation is provided by IL-1Ra, and upstream inducers include TLR4/LPS and TNF-??.
In renal cell carcinoma, IL-1?? derived from tumor cells is a key driver of a pro-tumorigenic inflammatory microenvironment that supports proliferation, angiogenesis, and immune modulation. Disruption of IL1B in the 769-P line allows researchers to assess how loss of IL-1?? alters NF-??B and MAPK signaling outputs, cytokine secretion profiles, and the expression of invasion-associated MMPs. This model is particularly suitable for exploring the role of IL-1?? in drug resistance and for testing whether pharmacological inhibition of the IL-1 pathway can restore drug sensitivity in ccRCC.
Common experimental applications include ELISA-based quantification of IL-1??, IL-6, and IL-8 to monitor cytokine networks; Western blot analysis of phosphorylated NF-??B p65, I??B??, JNK, p38, and ERK; RT-qPCR profiling of inflammatory gene expression; and NF-??B luciferase reporter assays to measure pathway activity. Functional studies can be conducted using MTT cell proliferation, wound healing migration, and Matrigel invasion assays. The polyclonal knockout population is also amenable to screening campaigns for IL-1 pathway or inflammasome inhibitors. For additional product information or technical support, please contact Ascent Research.
